Riskpilot← Back to searchSign inGet full accessFistulacath AB
ABActiveOrg 5568311145Hasselbacksgatan 7Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20100 employees
Revenue 2025
SEK 0
EBITDA margin
—
-500% vs 2024
Equity ratio
100.0%
Financial strength
Net profit 2025
SEK -22K
-83% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -12K | -500% |
| Net profit | SEK -22K | -83% |
| Total assets | SEK 32K | -41% |
| Equity | SEK 32K | -41% |
| Employees | 0 | — |
Legal name
Fistulacath AB
Org number
5568311145
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
9 december 2010
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Företaget ska bedriva utveckling och försäljning av medicintekniska produkter samt därmed förenlig verksamhet.
Address
Hasselbacksgatan 7
Email
ap@curemednordic.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −2 | −87 | −25 | −2 | −12 |
| Depreciation & amort. | −0 | −10 | −10 | −10 | −10 |
| EBIT | −2 | −97 | −35 | −12 | −22 |
| Net financials | — | — | — | — | — |
| Profit before tax | −2 | −97 | −35 | −12 | −22 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 | −97 | −35 | −12 | −22 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 66 | 54 | 61 | 54 | 32 |
| Equity | 48 | 51 | 56 | 54 | 32 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 18 | 3 | 5 | 0 | 0 |
| Total debt | 18 | 3 | 5 | — | — |
EBITDA margin
-1200000.0%
This company
15.8%
Market median
-7595037% vs market
20212025
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20212025
Return on equity
-68.8%
This company
18.4%
Market median
-474% vs market
20212025
Net profit margin
-2200000.0%
This company
8.1%
Market median
-27160594% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AP Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
EA Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Fistulacath AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arne Puhasmägi | Chief Executive Officer | 0 companies |
| Eva Ann-Christine Puhasmägi | Chief Executive Officer | 0 companies |
| Per Jörgen Ahlberg | Board of Directors | 0 companies |
| Lars Göran Ahlberg | Deputy Board Member | 0 companies |
| Erik Anders Petersén | Deputy Board Member | 0 companies |